RekrutujeFaza II
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Miasta: Bydgoszcz, Katowice, Kraków, Ostrowiec Świętokrzyski i 5 innych miastWiek: od 18 latSponsor: Pfizer Inc.
RekrutujeFaza II/III
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD)…
Miasta: Białystok, Elbląg, Katowice, Piaseczno i 2 inne miastaWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Miasta: Białystok, Poznań, Rzeszów, Sosnowiec i 1 inne miastoWiek: od 18 latSponsor: Glaxosmithkline Research & Development Limited
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Miasta: Białystok, Bydgoszcz, Chęciny, Elbląg i 13 innych miastWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 5 innych miastWiek: od 18 latSponsor: Glaxosmithkline Research & Development Limited
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Miasta: Białystok, Bydgoszcz, Chojnice, Chęciny i 25 innych miastWiek: od 18 latSponsor: Astrazeneca AB